From: Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
 |  |  |  | SMAD4 cytoplasmatic expression | SMAD4 nuclear expression | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | Total valid | Q123 | Q4 |  | HScore 0 present | HScore 0 absent | ||||||
 |  | n | (%) | n | (%) | n | (%) | p value | n | (%) | n | (%) | p value |
Total | Total | 463 | (100) | 366 | (79.1) | 97 | (20.9) | Â | 263 | (56.8) | 200 | (43.2) | Â |
Gender | Female | 178 | (38.4) | 144 | (80.9) | 34 | (19.1) | 0.482 | 90 | (50.6) | 88 | (49.4) | 0.034 |
 | Male | 285 | (61.6) | 222 | (77.9) | 63 | (22.1) |  | 173 | (60.7) | 112 | (39.3) |  |
Age group | < 68 years | 232 | (50.1) | 190 | (81.9) | 42 | (18.1) | 0.139 | 131 | (56.5) | 101 | (43.5) | 0.925 |
 | ≥ 68 years | 231 | (49.9) | 176 | (76.2) | 55 | (23.8) |  | 132 | (57.1) | 99 | (42.9) |  |
Localization | Proximal stomach | 145 | (31.0) | 123 | (84.8) | 22 | (15.2) | 0.049 | 93 | (64.1) | 52 | (35.9) | 0.033* |
 | Distal stomach | 318 | (69.0) | 243 | (76.4) | 75 | (23.6) |  | 170 | (53.5) | 148 | (46.5) |  |
Laurén phenotype | Intestinal | 237 | (51.2) | 186 | (78.5) | 51 | (21.5) | 0.313 | 149 | (62.9) | 88 | (37.1) | 0.026 |
Diffuse | 147 | (31.7) | 122 | (83.0) | 25 | (17.0) | Â | 73 | (49.7) | 74 | (50.3) | Â | |
 | Mixed | 31 | (6.7) | 24 | (77.4) | 7 | (22.6) |  | 19 | (61.3) | 12 | (38.7) |  |
 | Unclassifiable | 48 | (10.4) | 34 | (70.8) | 14 | (29.2) |  | 22 | (45.8) | 26 | (54.2) |  |
Grading | G1 / G2 | 107 | (23.1) | 82 | (76.6) | 25 | (23.4) | 0.499 | 62 | (57.9) | 45 | (42.1) | 0.824 |
 | G3 / G4 | 356 | (76.9) | 284 | (79.8) | 72 | (20.2) |  | 201 | (56.5) | 155 | (43.5) |  |
pT category | T1a / T1b | 58 | (12.5) | 38 | (65.5) | 20 | (34.5) | 0.011* | 32 | (55.2) | 26 | (44.8) | 0.923 |
 | T2 | 53 | (11.4) | 38 | (71.7) | 15 | (28.3) |  | 28 | (52.8) | 25 | (47.2) |  |
 | T3 | 182 | (39.3) | 150 | (82.4) | 32 | (17.6) |  | 108 | (59.3) | 74 | (40.7) |  |
 | T4a / T4b | 170 | (36.7) | 140 | (82.4) | 30 | (17.6) |  | 95 | (55.9) | 75 | (44.1) |  |
pN category | N0 | 132 | (28.5) | 99 | (75.0) | 33 | (25.0) | 0.151 | 69 | (52.3) | 63 | (47.7) | 0.399 |
 | N1 | 63 | (13.6) | 48 | (76.2) | 15 | (23.8) |  | 39 | (61.9) | 24 | (38.1) |  |
 | N2 | 85 | (18.4) | 70 | (82.4) | 15 | (17.6) |  | 49 | (57.6) | 36 | (42.4) |  |
 | N3a/b | 182 | (39.4) | 148 | (81.3) | 34 | (18.7) |  | 106 | (58.2) | 76 | (41.8) |  |
M category | M0 | 376 | (81.2) | 291 | (77.4) | 85 | (22.6) | 0.079 | 217 | (57.7) | 159 | (42.3) | 0.471 |
 | M1 | 87 | (18.8) | 75 | (86.2) | 12 | (13.8) |  | 46 | (52.9) | 41 | (47.1) |  |
UICC stage | IA / IB | 79 | (17.1) | 55 | (69.6) | 24 | (30.4) | 0.011* | 40 | (50.6) | 39 | (49.4) | 0.832 |
 | IIA / IIB | 99 | (21.4) | 77 | (77.8) | 22 | (22.2) |  | 59 | (59.6) | 40 | (40.4) |  |
 | IIIA / IIIB / IIIC | 197 | (42.6) | 158 | (80.2) | 39 | (19.8) |  | 118 | (59.9) | 79 | (40.1) |  |
 | IV | 87 | (18.8) | 75 | (86.2) | 12 | (13.8) |  | 46 | (52.9) | 41 | (47.1) |  |
Lymph node ratio | Low (< 0.189) | 226 | (48.9) | 175 | (77.4) | 51 | (22.6) | 0.426 | 126 | (55.8) | 100 | (44.2) | 0.639 |
High (≥ 0.189) | 236 | (51.1) | 190 | (80.5) | 46 | (19.5) |  | 137 | (58.1) | 99 | (41.9) |  | |
pL category | L0 | 216 | (48.8) | 167 | (77.3) | 49 | (22.7) | 0.645 | 112 | (51.9) | 104 | (48.1) | 0.069 |
 | L1 | 227 | (51.2) | 180 | (79.3) | 47 | (20.7) |  | 138 | (60.8) | 89 | (39.2) |  |
pV category | V0 | 393 | (88.9) | 308 | (78.4) | 85 | (21.6) | 0.856 | 225 | (57.3) | 168 | (42.7) | 0.446 |
 | V1 | 49 | (11.1) | 38 | (77.6) | 11 | (22.4) |  | 25 | (51.0) | 24 | (49.0) |  |
R status | R0 | 400 | (87.3) | 311 | (77.8) | 89 | (22.3) | 0.170 | 230 | (57.5) | 170 | (42.5) | 0.479 |
 | R1 / R2 | 58 | (12.7) | 50 | (86.2) | 8 | (13.8) |  | 30 | (51.7) | 28 | (48.3) |  |
HER2 status | Negative | 397 | (91.9) | 320 | (80.6) | 77 | (19.4) | 0.657 | 227 | (57.2) | 170 | (42.8) | > 0.999 |
 | Positive | 35 | (8.1) | 27 | (77.1) | 8 | (22.9) |  | 20 | (57.1) | 15 | (42.9) |  |
H. pylori status | Negative | 330 | (84.6) | 261 | (79.1) | 69 | (20.9) | 0.092 | 189 | (57.3) | 141 | (42.7) | 0.207 |
 | Positive | 60 | (15.4) | 41 | (68.3) | 19 | (31.7) |  | 29 | (48.3) | 31 | (51.7) |  |
EBV status | Negative | 428 | (95.5) | 341 | (79.7) | 87 | (20.3) | 0.273 | 242 | (56.5) | 186 | (43.5) | 0.821 |
 | Positive | 20 | (4.5) | 14 | (70.0) | 6 | (30.0) |  | 12 | (60.0) | 8 | (40.0) |  |
MSI status | MSS | 412 | (92.2) | 332 | (80.6) | 80 | (19.4) | 0.008* | 236 | (57.3) | 176 | (42.7) | 0.375 |
 | MSI | 35 | (7.8) | 21 | (60.0) | 14 | (40.0) |  | 17 | (48.6) | 18 | (51.4) |  |
p53 status | Quartile 1/Quartile 4 | 226 | (49.8) | 186 | (82.3) | 40 | (17.7) | 0.163 | 145 | (64.2) | 81 | (35.8) | 0.003 |
 | Quartile 2/Quartile 3 | 228 | (50.2) | 175 | (76.8) | 53 | (23.2) |  | 115 | (50.4) | 113 | (49.6) |  |
Overall survival [months] | Total / events / censored | 451 | Â | 347 / 289 / 68 | 94 / 62 / 32 | 0.001 | 257 / 210 / 47 | 194 / 141 / 53 | 0.035* | ||||
Median survival |  |  | 13.4 ± 1.1 | 22.4 ± 7.0 |  | 14.9 ± 1.4 | 15.6 ± 1.9 |  | |||||
95% C.I. |  |  | 11.3–15.5 | 8.7–36.0 |  | 12.2–17.6 | 12.9–17.1 |  | |||||
Tumor-specific survival [months] | Total / events / censored | 423 | Â | 333 / 236 / 97 | 90 / 51 / 39 | 0.002 | 240 / 173 / 67 | 183 / 114 / 69 | 0.038* | ||||
Median survival |  |  | 14.7 ± 1.4 | 30.3 ± 7.5 |  | 15.5 ± 1.6 | 18.4 ± 2.7 |  | |||||
95% C.I. |  |  | 12.0–17.3 | 15.5–45.0 |  | 12.4–18.5 | 13.1–23.8 |  |